From: Impact of bilateral biopsy-detected prostate cancer on an active surveillance population
Variable | Unilateral at biopsy (n = 186) | Bilateral at biopsy (n = 25) | p value |
---|---|---|---|
Clinical Presentation | median (IQR) | median (IQR) | – |
Age (years) | 58 (54–64) | 58 (55–61) | 0.78 |
PSA (ng/ml) | 5 (4–6.6) | 4.6 (4.2–5.9) | 0.51 |
PSAD | 0.12 (0.088–0.17) | 0.14 (0.1–0.18) | 0.48 |
BMI (kg/m2) | 29 (25.8–31.8) | 28.3 (25–33) | 0.86 |
US Vol (mL) | 41.7 (32.6–53.2) | 35 (25–42) | 0.03 |
Max core inv.% | 8 (5–20) | 8 (5–10) | 0.95 |
Grade Group | 1 | 1 | – |
Stage | 1 | ||
T1c | 172 (92.5%) | 24 (96%) | |
T2a | 14 (7.5%) | 1 (4%) | |
RP Pathology | – | ||
Prostate weight (g) | 45.4 (26–56.3) | 42.5 (34.1–52.9) | 0.28 |
Grade Group (Gleason) | 0.37 | ||
GG1 (3 + 3) | 106 (57%) | 15 (60%) | |
GG2 (3 + 4) | 72 (39%) | 8 (32%) | |
GG3 (4 + 3) | 6 (3%) | 1 (4%) | |
GG4 (4 + 4) | 1 (0.5%) | 1 (4%) | |
GG5 (4 + 5) | 1 (0.5%) | 0 | |
Upgrading | 80 (43%) | 10 (40%) | – |
% of tumor | 4% | 5% | 0.11 |
Pathologic Stage | 0.49 | ||
pT2a | 44 (23.7%) | 3 (12%) | |
pT2b | 2 (1.1%) | 0 | |
pT2c | 136 (73.1%) | 22 (88%) | |
pT3a | 4 (2.1%) | 0 | |
pT3b | 0 | 0 |